Antibiotics are one of the most common causes of moderate to severe immune-mediated drug reactions. However, many antibiotic reactions documented as allergies are unknown or not remembered by the patient. In addition, cutaneous reactions unrelated to drug hypersensitivity, drug-infection interactions, or drug intolerances can sometimes be confused as antibiotic allergies.
Although such reactions pose negligible risk to patients, they currently represent a global threat to public health. Antibiotic allergy labels result in displacement of first-line therapies for antibiotic prophylaxis and treatment.
Given the public health importance of antibiotic allergy, this Research Topic provides a global update on antibiotic allergy de-labeling and management.
As part of this section's mission to publish robust research on antibiotic allergy de-labelling, this Research Topic calls for papers covering, but not limited to the following themes:
- De-labeling penicillin allergy: populations at risk
- Cost/ benefit of de-labeling penicillin allergy
- Assessing penicillin allergy: Role of skin testing vs. direct oral challenge
- Penicillin allergy impact in the pediatric population
- Impact of penicillin allergy on surgical antibiotic prophylaxis
- Penicillin allergy and perioperative anaphylaxis
- Multidrug hypersensitivity syndrome: diagnosis and management
- Delayed reactions to beta lactam antibiotics
- Immediate reactions including anaphylaxis to beta lactam antibiotics
- Cross-reactivity between penicillin and cephalosporins : diagnosis and management
- Incidence and prevalence of beta lactam antibiotics allergy in the world
- Systematic approach and evaluation of beta lactam antibiotics allergy
- Beta lactam antibiotics allergy in children
- Safety of beta lactam antibiotics allergy evaluation in clinic
- (In-)appropriate overrides of clinical decision support warnings against antibiotic allergies
- De-labelling antibiotic allergy by natural language processing or machine learning
- Electronic phenotyping: True antibiotic allergy vs. hypersensitivity
All article types accepted by Frontiers are welcome.
Conflict of interest declarations: Miguel Park serves/served on the Data Safety Monitoring Board (DSMB) for a clinical trial for the company ImmunogenX. Mariana Castells Castells works with Blueprint as PI for two tryptase kinase inhibitor studies.
Antibiotics are one of the most common causes of moderate to severe immune-mediated drug reactions. However, many antibiotic reactions documented as allergies are unknown or not remembered by the patient. In addition, cutaneous reactions unrelated to drug hypersensitivity, drug-infection interactions, or drug intolerances can sometimes be confused as antibiotic allergies.
Although such reactions pose negligible risk to patients, they currently represent a global threat to public health. Antibiotic allergy labels result in displacement of first-line therapies for antibiotic prophylaxis and treatment.
Given the public health importance of antibiotic allergy, this Research Topic provides a global update on antibiotic allergy de-labeling and management.
As part of this section's mission to publish robust research on antibiotic allergy de-labelling, this Research Topic calls for papers covering, but not limited to the following themes:
- De-labeling penicillin allergy: populations at risk
- Cost/ benefit of de-labeling penicillin allergy
- Assessing penicillin allergy: Role of skin testing vs. direct oral challenge
- Penicillin allergy impact in the pediatric population
- Impact of penicillin allergy on surgical antibiotic prophylaxis
- Penicillin allergy and perioperative anaphylaxis
- Multidrug hypersensitivity syndrome: diagnosis and management
- Delayed reactions to beta lactam antibiotics
- Immediate reactions including anaphylaxis to beta lactam antibiotics
- Cross-reactivity between penicillin and cephalosporins : diagnosis and management
- Incidence and prevalence of beta lactam antibiotics allergy in the world
- Systematic approach and evaluation of beta lactam antibiotics allergy
- Beta lactam antibiotics allergy in children
- Safety of beta lactam antibiotics allergy evaluation in clinic
- (In-)appropriate overrides of clinical decision support warnings against antibiotic allergies
- De-labelling antibiotic allergy by natural language processing or machine learning
- Electronic phenotyping: True antibiotic allergy vs. hypersensitivity
All article types accepted by Frontiers are welcome.
Conflict of interest declarations: Miguel Park serves/served on the Data Safety Monitoring Board (DSMB) for a clinical trial for the company ImmunogenX. Mariana Castells Castells works with Blueprint as PI for two tryptase kinase inhibitor studies.
